Acute upper airway obstruction caused by Stenotrophomonas maltophilia soft tissue infection

Scandinavian Journal of Infectious Diseases

Volumn 37, Issue 10, 2005, Pages 734-737

  Bello, Guiseppe ^a   Pennisi, Mariano Alberto ^a   Fragasso, Tiziana ^a   Mignani, Vittorio ^a   Antonelli, Massimo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; COTRIMOXAZOLE; IMIPENEM; LEVOFLOXACIN; LINEZOLID;

AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL GROWTH; BACTERIUM CULTURE; CALIBRATION; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; ENDOTRACHEAL INTUBATION; FOLLOW UP; HUMAN; INTENSIVE CARE UNIT; LARYNGOSCOPY; LUNG LAVAGE; MALE; NONHUMAN; PLEURA EFFUSION; SOFT TISSUE INFECTION; STENOTROPHOMONAS MALTOPHILIA; THORAX RADIOGRAPHY; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; UPPER RESPIRATORY TRACT OBSTRUCTION;

AGED; AIRWAY OBSTRUCTION; HUMANS; MALE; OROPHARYNX; SOFT TISSUE INFECTIONS; STENOTROPHOMONAS MALTOPHILIA; THYROID GLAND; TOMOGRAPHY, X-RAY COMPUTED;

EID: 27744434164     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540510044436     Document Type: Article

References (13)

1. Muder RR, Harris AP, Muller S, Edmond M, Chow JW, Papadakis K, et al. Bacteraemia caused by Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicentre study of 91 episodes. Clin Infect Dis 1996;22: 508-12.
2. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998;11:57-80.
3. Vartivarian SE, Papadakis KA, Palacios JA, Manning JT Jr, Anaissie EJ. Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia: a new spectrum. Ann Intern Med 1994;121:969-73.
4. Jaber S, Chanques G, Matecki S, Ramonatxo M, Vergne C, Souche B, et al. Post-extubation stridor in intensive care unit patients. Risk factors evaluation and importance of the cuff-leak test. Intensive Care Med 2003;29:69-74.
5. Laing FP, Ramotar K, Read RR, Alfieri N, Kureishi A, Henderson EA, Louie TJ. Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment. J Clin Microbiol 1995;33:513-8.
6. Schaumann R, Stein K, Eckhardt C, Ackermann G, Rodloff AC. Infections caused by Stenotrophomonas maltophilia: a prospective study. Infection 2001;29:205-8.
7. Sakhnini E, Weissmann A, Oren I. Fulminant Stenotrophomonas maltophilia soft tissue infection in immunocompromized patients: an outbreak transmitted via tap water. Am J Med Sci 2002;323:269-72.
8. Weiss K, Restieri C, De Carolis E, Laverdiere M, Guay H. Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 2000;45:363-5.
9. Bonfiglio G, Cascone C, Azzarelli C, Cafiso V, Marchetti F, Stefani S. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates. J Antimicrob Chemother 2000;45:115-7.
10. Betriu C, Sanchez A, Palau ML, Gomez M, Picazo JJ. Antibiotic resistance surveillance of Stenotrophomonas maltophilia, 1993-1999. J Antimicrob Chemother 2001;48: 152-4.
11. Gesu GP, Marchetti F, Piccoli L, Cavallero A. Levofloxacin and ciprofloxacin in vitro activities against 4003 clinical bacterial isolates collected in 24 Italian laboratories. Antimicrob Agents Chemother 2003;47:816-9.
12. Lanzafame A, Bonfiglio G, Santini L, Mattina R. In vitro activity of levofloxacin against recent Gram-negative nosocomial pathogens. Chemotherapy 2005;51: 44-50.
13. Bellmann R, Kuchling G, Dehghanyar P, Zeitlinger M, Minar E, Mayer BX, et al. Tissue pharmacokinetics of levofloxacin in human soft tissue infections. Br J Clin Pharmacol 2004;57:563-8.